

REMARKS


Claims 1-8, 16-21, 25-27, 40, 41, 49, 57, 65, 73, 84, 92, and 99 remain for consideration in the above-identified patent application, claims 9-15, 22-24, 28-39, 42-48, 50-56, 58-64, 66-72, 74-83, 93-98, and 100-106 having been cancelled by this Preliminary Amendment.

This Preliminary Amendment is made solely to reduce claim number.  
This Preliminary Amendment is made for no other reason.

Specifically, the amendments to claims 40, 41, 49, 57, 65, 73, 84, 92, and 99 are made to place all additional therapeutic agents in a single claim, claim 40, and then to correct the dependencies of claims reciting specific alternatives for additional therapeutic agents so that they are consistent with the recitation of all additional therapeutic agents in claim 40.

Accordingly, the amendments to the claims introduce no new matter.  
Therefore, entry of the amendments to the claims is respectfully requested.

Respectfully submitted,



Michael B. Farber, Ph.D., Esq.  
Reg. No.: 32,612

Date: April 3, 2006  
CATALYST LAW GROUP, APC  
9710 Scranton Road, Suite 170  
San Diego, California 92121  
(858) 450-0099  
(858) 450-9834 (Fax)